 Hydroxyurea
"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
| Descriptor ID |
D006918
|
| MeSH Number(s) |
D02.948.395
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".
This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 1 | 0 | 1 | | 1985 | 0 | 1 | 1 | | 1986 | 1 | 0 | 1 | | 1987 | 0 | 1 | 1 | | 1988 | 1 | 1 | 2 | | 1989 | 1 | 1 | 2 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 2 | 2 | | 1992 | 5 | 2 | 7 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 4 | 4 | | 1995 | 0 | 6 | 6 | | 1996 | 1 | 1 | 2 | | 1997 | 1 | 1 | 2 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2003 | 2 | 5 | 7 | | 2004 | 1 | 1 | 2 | | 2005 | 2 | 2 | 4 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 3 | 4 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 5 | 5 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
-
Creary SE, Beeman C, Stanek J, King K, McGann PT, O'Brien SH, Liem RI, Holl J, Badawy SM. Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. Pediatr Blood Cancer. 2022 06; 69(6):e29607.
-
Kayle M, Valle J, Paulukonis S, Holl JL, Tanabe P, French DD, Garg R, Liem RI, Badawy SM, Treadwell MJ. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease. Pediatr Blood Cancer. 2020 05; 67(5):e28152.
-
Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):297-308.
-
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.
-
Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 Jan; 176(1):76-85.
-
Indik JH, Nair V, Rafikov R, Nyotowidjojo IS, Bisla J, Kansal M, Parikh DS, Robinson M, Desai A, Oberoi M, Gupta A, Abbasi T, Khalpey Z, Patel AR, Lang RM, Dudley SC, Choi BR, Garcia JG, Machado RF, Desai AA. Associations of Prolonged QTc in Sickle Cell Disease. PLoS One. 2016; 11(10):e0164526.
-
Rivers A, Vaitkus K, Ruiz MA, Ibanez V, Jagadeeswaran R, Kouznetsova T, DeSimone J, Lavelle D. RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases ?-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model. Exp Hematol. 2015 Jul; 43(7):546-53.e1-3.
-
Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
-
Minogue PJ, Beyer EC, Berthoud VM. A connexin50 mutant, CX50fs, that causes cataracts is unstable, but is rescued by a proteasomal inhibitor. J Biol Chem. 2013 Jul 12; 288(28):20427-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|